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“I am among those who think that science has great beauty. A scientist in his laboratory is  
not only a technician: he is also a child placed before natural phenomena which impress him  
like a fairy tale.” 
 Marie Curie
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Resumo 
Os vírus da imunodeficiência adquirida tipo 1 (HIV-1), hepatite C (HCV) e hepatite B (HBV) 
constituem uma ameaça mundial para a saúde pública. Estatísticas recentes sugerem que 
milhões de pessoas possuem SIDA, hepatite C ou B, sendo que co-infeções entre estes três 
vírus são relativamente comuns devido à partilha de rotas de transmissão. Por este motivo, um 
melhor diagnóstico destas infeções e co-infeçoes é vital para monitorizar estas doenças 
infeciosas e controlar epidemias. 
Um marco importante no diagnóstico clínico consistiu na implementação de testes serológicos 
baseados na deteção de antigénios e anticorpos antivirais. De uma forma geral, testes 
serológicos fazem a deteção indireta dos vírus, estando por isso sujeitos a falsos negativos, 
como é exemplo a elevada taxa de falsos negativos no período janela da infeção. De forma a 
evitar estes problemas, várias técnicas baseadas em ácidos nucleicos têm sido introduzidas 
para deteção direta destes vírus, com especial relevância no controlo da qualidade das 
doações para bancos de sangue. 
A sensibilidade das técnicas baseadas em ácidos nucleicos aumentou consideravelmente com 
o aparecimento da reação em cadeia da polimerase (PCR), que permite a amplificação de 
secções do genoma viral partindo de uma quantidade pequena de amostra. De entre as várias 
técnicas disponíveis, as mais utilizadas são o PCR em tempo real, essencialmente utilizado na 
quantificação de cargas virais e monotorização da resposta às terapias antivirais, e o multiplex 
PCR, onde várias regiões são amplificadas em simultâneo permitindo a identificação viral. No 
entanto, a grande maioria dos métodos atualmente disponíveis baseiam-se na análise de uma 
única região do genoma viral (estando sujeitos a falsos negativos) ou requerem várias reações 
independentes, o que aumenta significativamente o custo do diagnóstico. Desta forma, é 
urgente o desenvolvimento de métodos que detetem simultaneamente vários vírus numa só 
reação. 
Nesta dissertação é descrito o desenvolvimento de três PCR multiplex para a deteção do HIV-
1, HCV e HBV e um multiplex PCR para a deteção simultânea destes três vírus. Após o 
alinhamento de várias sequências genómicas de cada vírus, 33 pares de primers de PCR 
foram desenhados para amplificação por PCR de oito regiões genómicas no HIV-1, 14 no HCV 
e 11 no HBV. Destas regiões, cinco foram amplificadas com sucesso em PCR singleplex para o 
HIV-1, sete para o HCV e 11 para o HBV. 
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De seguida, cinco regiões para o HIV-1 e HBV e seis para o HCV foram incluídas nos PCR 
multiplex individuais de forma a obter amplificações com tamanhos diferentes. Deste modo, 
cada vírus é identificado pela amplificação de diferentes regiões genómicas que resultam num 
padrão específico de bandas observáveis em eletroforese.  
A eficácia dos PCR multiplex foi testada em 70 amostras de plasma de indivíduos residentes 
em Portugal e na Escócia infetados com estes vírus (32 com HIV-1, 26 com HCV, oito com 
HBV, três co-infeções HIV-1/HCV e uma co-infeção HIV-1/HBV). A deteção dos vírus foi 
concretizada pela visualização dos produtos amplificados em gel de agarose.  
Os resultados comprovam que pelo menos uma região genómica foi sempre amplificada em 
todas as amostras. Das amostras de HIV-1, 31 % foram amplificadas para as cinco regiões, 
sendo representativas dos vários genótipos do HIV-1 (B, C, G e recombinantes). Metade das 
amostras de HCV pertencentes a diferentes genótipos (1A e 3) foram amplificadas para as seis 
regiões. No caso do HBV, 33 % das amostras foram amplificadas com todos os pares de 
primers testados. Em média, 3,31 regiões foram amplificadas no HIV-1, 4,54 regiões no HCV e 
3,44 regiões no HBV. Estes testes demonstram que os PCR multiplex permitem a correta 
deteção dos vírus independentemente dos genótipos e em amostras com diferentes 
proveniências. 
De forma a demostrar a robustez dos PCR multiplex, foram realizados testes de sensibilidade 
através de amplificações PCR com gradientes de temperatura de annealing e com gradientes 
de concentrações virais (i.e., diluições em série). Os resultados indicam que o intervalo ideal de 
funcionamento dos três PCR multiplex em termos de temperaturas de annealing é de 54,5 °C a 
58,3 °C. No entanto, algumas regiões amplificaram em temperaturas fora deste intervalo, 
sugerindo que mesmo em diferentes condições podem permitir a deteçao viral. Os limites de 
deteção em termos de carga viral foram estimados para 343,75 cópias/mL para o HIV-1, 418,56 
UI/mL para o HCV e 19,92 UI/mL para o HBV. Estes limites de deteção sugerem que os PCR 
multiplex são adequados ao diagnóstico viral durante o período janela. Foram ainda realizados 
alguns testes adicionais onde ficou evidente que os PCR multiplex são específicos e não 
originam amplificações na presença de material genético humano ou de outros vírus. 
Por fim, foram selecionadas duas regiões de cada vírus para serem incluídas no PCR multiplex 
para a deteção simultânea de HIV-1, HCV e HBV. A escolha das regiões foi realizada tendo em 
consideração o sucesso de amplificação dos vários marcadores incluídos nos PCR multiplex 
individuais, bem como a conjugação de tamanhos dos produtos de PCR de forma a obter um 
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padrão de bandas identificadoras de cada vírus. Este multiplex foi testado em amostras de 
indivíduos co-infetados (duas HIV-1/HCV e uma HIV1/HBV) e em amostras de misturas 
artificiais de material genético dos diferentes vírus. Em todas as amostras foi possível a correta 
deteçao dos vírus presentes na mistura, com exceção de uma co-infeção HIV-1/HCV onde o 
HIV-1 não foi detetado, muito provavelmente devido à baixa carga viral deste vírus na amostra 
(41cópias/mL).  
Uma das grandes vantagens dos métodos propostos nesta dissertação é a localização dos 
primers em regiões genómicas conservadas (i.e., com poucos polimorfismos), o que permite a 
deteção de vários genótipos. No entanto, os vários marcadores testados têm diferentes 
eficácias de amplificação nas amostras testadas. Este facto poderá dever-se à extrema 
variabilidade genética presente nestes vírus (especialmente os de RNA, HIV-1 e HCV), às 
baixas cargas virais de algumas amostras (especialmente em infeções com HIV-1) ou resultar 
de outros fatores inerentes ao próprio PCR (por exemplo, interações entre primers). No 
entanto, a ausência de amplificação de alguns marcadores em algumas amostras não impediu 
a deteçao dos diferentes vírus. Mesmo que uma ou mais regiões não sejam amplificadas, uma 
correta deteção dos vírus é possível com os nossos PCR multiplex devido ao uso de vários 
marcadores em simultâneo, o que constitui uma vantagem em relação aos métodos que 
utilizam apenas um par de primers.  
Em conclusão, os métodos apresentados nesta dissertação são adequados para a identificação 
de HIV-1, HCV e HBV (separadamente ou em simultâneo) em casos de co-infeções ou quando 
não é adequado a utilização de testes serológicos (por exemplo, no período pré-seroconversão 
e em recém-nascidos). O PCR multiplex para a deteção de vários vírus na mesma reação 
facilita a análise de amostras em grande escala, ao permitir uma redução nos custos e no 
tempo de diagnóstico. Desta forma, estes PCR multiplex poderão ser usados em amostras 
obtidas em contexto clínico e em bancos de doação de sangue, aumentando o rigor da deteção 
e a rapidez na obtenção de resultados. 
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Abstract 
Human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and hepatitis B virus 
(HBV) are a signiﬁcant threat to public health worldwide. Several serological and nucleic acid 
assays are used for the correct detection of these viruses. However, most detection methods 
lack accuracy and are expensive and time-consuming. It is therefore of paramount importance 
to develop methods for the simultaneous identification of different viruses at low cost and with 
high accuracy. 
In this thesis, one multiplex PCR for the simultaneous identification of HIV-1, HCV and HBV and 
three multiplex PCRs for identification of each virus are described. A total of 33 primer pairs 
were designed in conserved genomic regions for detection of different genotypes. Primers were 
initially tested by singleplex PCR and five (for HIV-1 and HBV) and six (for HCV) primers pairs 
were selected for final multiplex PCRs. Because the target regions were selected with a unique 
combination of lengths, each virus can be identified by band pattern analysis. The reproducibility 
of the assays was tested in 70 plasma samples from infected individuals. All samples yielded 
positive amplifications, with 31.3 % (HIV-1), 50 % (HCV) and 33.3 % (HBV) of the samples 
amplified for all target regions. The multiplex PCR for simultaneous detection of the three 
viruses successfully identified 83.3 % of the co-infected samples. Finally, multiplex PCRs 
proved to be specific and had low detection limits: 343.75 copies/mL for HIV-1, 418.56 IU/mL for 
HCV and 19.92 IU/mL for HBV.   
The main advantages of these assays are the use of multiple targets (avoiding false-negative 
results), use of PCR primers designed in conserved genomic regions (increasing the specificity), 
use of low cost laboratory equipment and the suitability for identification of co-infections. 
Overall, these assays can be used for a rapid screening of samples in clinical diagnostic or 
blood banks. 
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Introduction 
Some of the most devastating diseases and epidemics in human history were caused by viral 
infections. Coupled with disease and death, viruses can also be the cause of significant chronic 
diseases and cancers [1]. The human immunodeficiency virus type 1 (HIV-1), hepatitis C virus 
(HCV) and hepatitis B virus (HBV) are among the most dangerous viruses to humans, being a 
signiﬁcant threat to public health worldwide [2]. HIV-1 is associated with the acquired 
immunodeficiency syndrome (AIDS), which leaves patients open to a wide variety of other 
opportunistic infections. The latest statistics of the global HIV-1 epidemic show that there are 35 
million people living with HIV/AIDS and that 1.5 million AIDS deaths occurred in 2013 [3]. HCV 
and HBV are both responsible for hepatitis and for hepatocellular carcinoma and cirrhosis. 
Chronic hepatitis C affects 130-150 million people worldwide [4], while more than 240 million 
people are infected with HBV [5]. HCV and HBV are also the leading cause of liver cancer in the 
world, accounting for 78 % of the reported cases [6]. A vaccine against hepatitis B has been 
available since 1982, but unfortunately no effective vaccines exist for HIV-1 and HCV.  
There is a remarkable prevalence of co-infections among these viruses, which is related to the 
sharing of same transmission routes, such as blood and blood products [7]. Individuals with 
HCV/HBV co-infection tend to have more severe liver injuries, a high probability of liver cirrhosis 
and to develop hepatocellular carcinoma. The prevalence of HCV/HBV co-infections remains 
unknown, despite its clinical importance and the interest on its diagnosis for improved treatment. 
Some studies reveal that HCV/HBV co-infections are common in highly endemic areas and 
among subjects with a high risk of parenteral infections [8]. Moreover, it has been clearly shown 
that HCV and HBV infections are highly prevalent among HIV-1 infected individuals [9]. In HIV-1 
infected individuals, about 10 - 12.5 % have HCV co-infection and 5 - 10 % have chronic HBV 
co-infection [7]. The clinical importance of HIV-1/HCV co-infection has increased over the last 
years since HCV-related liver disease has emerged as a major cause of deaths in HIV-1 
infected patients treated with highly active anti-retroviral (HAART) [10]. 
The genomic structure of these three viruses varies considerably. While HIV-1 and HCV are 
single stranded RNA viruses, HBV is a partially double stranded DNA virus. Moreover, HIV-1 is 
a retrovirus and its RNA is reverse transcript in a double strand DNA and randomly integrated 
into cell genome (provirus), while HCV RNA serves as viral messenger RNA being directly 
translated. The HBV genome is considerably smaller (3.2 kbp) than those of HIV-1 (9.75 kb) 
and HCV (10 kb) [11]. 
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The different genomic types are associated with different mutational rates and, consequently, 
with varied degrees of genetic variability. In general, mutation rates are considerably higher in 
RNA viruses than in DNA viruses, due to high error rates of the RNA-dependent RNA 
polymerases when compared with DNA-dependent DNA polymerases during genome 
replications [1]. The high genetic variability observed in viruses, especially RNA viruses, makes 
their molecular diagnosis very problematic since it is difficult to design effective methods (e.g. 
PCR primers or probes) to accurately target the highly polymorphic genomic regions. 
The correct detection of these three pathogenic blood-borne viruses is crucial for the 
management of the infectious diseases. The development of sensitive serological tests has 
improved significantly the efficacy of viral detection. For instance, HIV-1 and HCV screening is 
done mostly by detection of antiviral antibodies, while HBV screening is achieved by detection 
of surface antigen (HBsAg) [12-14]. In addition to antibodies detection, HIV-1 can also be 
detected by p24 antigen tests, which allows direct detection of the virus. However, p24 antigen 
tests have a high rate of false-positives [15].  
Serological tests are considered indirect detection methods. Therefore, residual risks of false-
negatives emerge related to the pre-seroconversion window period, immunosilent carriage, 
infection with immunovariant viruses and, in case of HBV infection, due to occult carriage [16-
18]. These diagnostic failures are serious concerns in blood donor centers, where screening 
must be done correctly. In fact, HIV-1, HCV and HBV are the most important infectious agents 
transmitted by blood transfusion [19, 20].  
In order to overcome some of the serological shortcomings, a number of nucleic acid techniques 
(NATs) have been developed for direct detection of pathogens [21]. These molecular 
techniques have been used for multiple applications, namely in the direct detection of 
pathogens in clinical samples, genetic characterization of isolates, identification of genotype 
variations, determination of viral loads and detection of drug resistance mutations [22]. 
Molecular diagnostic is currently applied by many laboratories worldwide, using diverse 
techniques such as nucleic acid probes hybridization, ligase chain reaction, transcription-based 
amplification system and polymerase chain reaction (PCR) [22].  
The advent of the PCR technique has increased significantly the sensitivity of NATs by allowing 
the amplification of viral nucleic acid from low quantities, while retaining a high specificity [23]. 
Several PCR-based systems are now available for viral detection and are increasingly applied in 
clinical and research virology [24-26]. The reverse transcriptase (RT)-PCR, nested PCR and 
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multiplex PCR are some of the most commonly used PCR assays [21]. Moreover, several 
techniques are also available for the analysis of the PCR amplified products, including agarose 
gel or capillary electrophoresis. More complex techniques are also available such as 
hybridization protection assay (HPA), DNA sequencing, RFLP analysis or DNA enzyme 
immunoassay (DEIA) [22].   
However, NATs have some disadvantages, such as the high cost and the need for 
sophisticated laboratory equipment. By these reasons, NATs are difficult to apply on a large-
scale routine screening and solutions are required to reduce screening time and costs [27]. 
Nevertheless, NATs have been an invaluable help in the prevention of infections, especially 
when accuracy is critical as in the screening of blood donations [19, 28].  
In order to overcome the limitations inherent to the large-scale implementation of NATs, 
researchers often use a panel detection system to screen for several viruses simultaneously. In 
this regard, two different approaches have been used [29]. One method is based on the parallel 
analysis of a pool of samples in a single reaction or tube. However, some studies suggest that 
this approach reduces the sensitivity of the detection since the dilution of samples results in 
lower amounts of nucleic acid available for each individual amplification, which can lead to a 
high rate of false-negative results [30]. 
Another option involves the use of multiplex assays for detection of several targets 
simultaneously [29]. The simultaneous detection of several target sequences in a single 
reaction is a good option for saving time, effort and costs within the laboratory, without 
compromising results. It is also a good solution when test sample volume is limited, since 
various reactions can be performed simultaneously. Among the different available multiplex 
options, real-time PCR assays are the most used since they allow the quantification of viral 
loads. This method is therefore very effective to monitor disease progression and response to 
therapy, which is vital to the management of chronic infectious diseases. However, real-time 
PCR assays have a limited multiplex detection capacity due to the reduced number of 
fluorophores that could be combined and clearly distinguished. The available wave-lengths in 
existing equipment currently allows the detection of only three or four targets simultaneously 
[29, 31]. In order to screen for various viruses and/or target genomic regions, independent 
reactions in different tubes or plates have to be carried out [26]. Nevertheless, most detection 
assays to HIV-1, HCV and/or HBV are based on real-time PCR [32-35], with only a few using 
conventional PCR [36, 37]. These multiplex approaches require careful optimization of all 
parameters to avoid a decrease in sensitivity [38]. 
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In general, available viral detection assays are either limited by the need to perform multiple 
reactions, or by the number of genomic regions used to identify each virus. Most methods 
targeting different genomic regions require multiple and independent reactions [26, 33]. On the 
other hand, methods that produce results on a single reaction are limited by the number of 
targets that can be simultaneously analyzed, for instance in real-time PCR. In most of these 
cases, a single genomic region is targeted, which makes these methods highly prone to false 
negative results caused by missing amplifications due to sequence variation in primer or probe 
binding sites [31]. 
As an alternative to real-time PCR, conventional multiplex PCR has been successfully applied in 
many areas of species identification and has been also successfully applied in molecular 
diagnosis. Recently, multiplex PCR was used as a valuable method for pathogenic identification 
of bacteria, fungi and viruses [38]. Because several targets are used for the identification, the 
confidence of the results is higher than when using singleplex PCR assays [39, 40]. Methods 
that produce results on a single reaction are highly prone to false negative results, which is less 
likely to occur in multiplex PCRs with several target regions for each virus [31]. Multiplex PCR is 
also suitable to detect viral co-infections, for instance by producing amplicons with different 
lengths for each virus, which results in a detectable band pattern [36]. 
The aim of the present dissertation is to develop individual multiplex PCR assays for the 
identification of HIV-1, HCV and HBV and one multiplex PCR assay for the simultaneous 
identification of the three viruses. The multiplex PCRs will include PCR primers designed in 
conserved regions of the viral genomes for an efficient detection of different genotypes. 
Moreover, target regions will be selected with a unique combination of lengths for each virus, 
allowing their unequivocal detection by fragment length analysis in agarose gel electrophoresis. 
The long-term objective of this work is to develop multiplex PCR assays that can be used in 
problematic cases, including viral co-infections, detection of infections in the pre-seroconversion 
window period, seronegative or immunocompromised individuals and also to resolve 
indeterminate serologic results. Overall, these multiplex PCR assays will be tested as useful 
tools for rapid clinical diagnostic and blood-banks screenings. 
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Material and methods 
Sequence alignments 
Three multiple sequence alignments with full or nearly full genomic sequences from HIV-1, HCV 
and HBV were used. The ‘HIV-1/SIVcpz compendium 2012’ alignment was downloaded from 
the Los Alamos public database [41]. This alignment corresponds to a carefully chosen subset 
of sequences printed in the HIV sequence compendium [42] and was built using HMMER [43] 
and edited manually to keep the reading frames intact. The HIV-1 alignment includes 170 
genomic sequences representing the HIV-1 M group subtypes A (n=16), B (n=36) C (n=21), D 
(n=11), F (n=11), G (n=9), H (n=4), J (n=3), K (n=2) and recombinant forms (n=57). The HIV-1 
reference sequence with GenBank accession number K03455.1 was also included in the 
alignment. 
The HCV sequence alignment was downloaded from the HCV database project [44]. We used 
the ‘HCV Web alignment 2008’ with 471 complete genome sequences, which is a manually 
edited alignment including only one sequence from patient. Moreover, very similar or 
epidemiologically related groups are only represented in the alignment by one sequence. All 
HCV genotypes are represented in the alignment, namely genotypes 1 (n=378), 2 (n=29), 3 
(n=7), 4 (n=11), 5 (n=3), 6 (n=43). The HCV reference sample with GenBank accession number 
NC_004102.1 was used.  
Regarding HBV, no curated sequence alignments were available in public databases. 
Therefore, we built a multiple sequence alignment with complete HBV genome sequences 
retrieved from the NCBI Entrez Nucleotide database [45] representing distinct genotypes 
sampled across different world regions. We selected 386 sequences distributed by genotypes A 
(n=37), B (n=16), C (n=120), D (n=100), E (n=53), F (n=35), G (n=3) and H (n=22), according to 
the classification provided by Harrison et al [46]. The HBV reference sequence with GenBank 
accession number EU054331.1 was used. The sequences were aligned using the default 
parameters of the Muscle software [47]. All sequence alignment can be found in the IGVID 
database associated with this work [48]. 
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Selection of target regions and PCR primer design  
Target regions were selected to be included in the multiplex PCRs using the sequence 
alignments and considering the following criteria: 1) each region had to have a conserved length 
across the multiple sequence alignments (i.e., low intra-virus diversity in sequence length); 2) 
the different target regions of each virus had to be of different lengths to allow their combination 
in a multiplex PCR and 3) the target regions had to be bounded by conserved regions of 17 to 
26 nucleotides to allow the design of PCR primers.  
In order to design PCR primers that specifically delimit the selected target genomic regions in a 
multiplex PCR, several criteria were taking into account: 1) the potential primers were designed 
to avoid variable positions in the last fivA volume of 460 µL of supernatant was removed and the 
remaining 140 µL of pellet was used as input for the viral RNA extraction protocol. e 3’ end 
positions; 2) primers were designed with a predicted melting temperature between 57 to 62 °C, 
estimated in the OligoCalc website [49]; 3) primers were tested in the AutoDimer v1 program 
[50] to avoid primer-dimer and hairpin interactions and 4) pairs of primers were compared with 
the human and viral genomes using the NCBI Basic Local Alignment Search Tool [51] to avoid 
nonspecific amplifications. 
The following nomenclature was implemented for target regions and PCR primers: ‘Virus 
name_amplicon length in reference sequence’ to designate the target regions. For example, 
HBV_101 indicates a target region for HBV with 101 nucleotides (nt). The only exception for this 
nomenclature regards HIV-1_LTR, which indicates a HIV-1 target region in the long terminal 
repeat (LTR) region and it does not indicate the amplicon length. The nomenclature ‘Virus name 
_ primer position in reference sequence_F or R’ was used to designate the name of PCR 
primers. For instance, HCV_16F indicates a forward PCR primer for HCV starting at position 16 
of the reference genome sequence. 
  
Plasma samples 
A total of 70 plasma samples were tested in this work, including 43 from infected individuals 
living in Scotland (24 infected with HIV-1 and 19 with HCV) and 27 from individuals living in 
Portugal (eight infected with HIV-1, seven with HCV, eight with HBV, three with HIV-1/HCV co-
infections  and one with HIV-1/HBV co-infection). The infectious state of the individuals was 
previously determined by immunological methods and the viral load quantified by real time PCR 
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in the Medical Research Council, Centre for Virus Research, University of Glasgow, Scotland 
and Santo António Hospital, Porto, Portugal. 
The 32 HIV-1 samples are from the most frequent group M, namely from subtypes B (n=11), C 
(n=10), A1 (n=2), G (n=2) and complex/recombinants (n=5). The subtype of two samples is 
unknown. The HIV-1 viral loads in the samples ranged from 111 to 544,436 copies/mL. The 26 
HCV samples represent genotypes 3 (n=2), 1A (n=9), 4 (n=1) or have an unknown genotype 
(n=4) and have viral loads ranging from 2,670 to 11,000,000 IU/mL. The eight HBV samples 
represent genotype A (n=2), D (n=3) or have an unknown genotype (n=4). The HBV viral loads 
range from 20 to 170,000,000 IU/mL. We also used samples from individuals with co-infections, 
namely one with HIV-1/HBV and three with HIV-1/HCV. Table 1 of supplementary material 
provides detailed information for all samples. 
The samples were aliquoted and stored at -80 °C and were only frozen and thawed twice prior 
to testing. Ethical permission for using all samples in the present study was obtained in each 
country through the appropriate committees. 
 
RNA isolation and cDNA synthesis 
RNA was extracted from 600 µL of HIV-1, HCV and HIV-1/HCV co-infected plasma specimens 
using the QIAamp Viral RNA Mini Assay (Qiagen, Valencia, CA). Virions were initially 
concentrated from the plasma by centrifugation at full speed (16,873 g) for three hours. A 
volume of 460 µL of supernatant was removed and the remaining 140 µL of pellet was used as 
input for the viral RNA extraction protocol.  Extracted RNA was eluted with 60 µL of AVE buffer 
provided in the extraction kit, aliquoted and stored at -80 ºC until use. 
For HBV and HIV-1/HBV co-infected plasma specimens, DNA and RNA were extracted from 
200 µL initial volume using PureLink®Viral RNA/DNA Kits (Invitrogen Life Technologies, 
Carlsbad, CA). The extracted DNA and RNA was eluted with 50 µL of sterile RNase-free water 
provided in the extraction kit, aliquoted and stored at -20 ºC (HBV samples) and -80 ºC (HIV-
1/HBV co-infection) until use. 
Reverse transcription of HIV-1 and HCV samples was performed using the SuperScriptTM III 
Reverse Transcriptase (Invitrogen Life Technologies) and random hexamer primers. Briefly, 10 
µL of HCV RNA or 5 µL of HIV-1 RNA were used in each reaction. Extracted RNA was reverse 
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transcribed in a total volume of 20 µL with 1 µL of dNTPs at 10 mM, 1 µL of random hexamer 
primers (50 µM) and 2 µL (in case of HCV) or 5 µL (in case of HIV-1) of water DNase, RNase- 
and protease-free (5 Prime, Germany). The RNA, dNTPs, random hexamer primers and water 
were first incubated at 65 ºC for 5 min and 4 ºC for 5 min. Then, 4 µL of 5X First-Strand Buffer, 
1 µL of DTT (0.1 M), 0.5 µL of RNaseOUT and 0.5 µL of SuperScriptTM III RT (Invitrogen Life 
Technologies) were incubated at 50 ºC for 60 min and 70 ºC for 15 min. 
 
Singleplex and multiplex PCR amplifications 
Initially, two samples of each virus (1IV001 and 1IV003 for HIV-1, CV001 and CV002 for HCV 
and BV013 and BV839 for HBV) were used to test all primers in singleplex reactions. The PCR 
was prepared in a total volume of 10 μL as follows: 5 μL of Multiplex PCR Master Mix (Qiagen, 
Valencia, CA), 1 μL of forward primer (2 µM), 1 μL of reverse primer (2 µM), 2 μL of water 
DNase, RNase- and protease-free (5 Prime) and 1 μL of viral cDNA/DNA. The thermocycling 
conditions were: initial step at 95 ºC for 15 min; 40 cycles for HIV-1 and 35 cycles for HCV and 
HBV at 94 ºC for 30 s, 55 ºC for 1 min 30 s, 72 ºC for 1min; with a final extension at 72 ºC for 10 
min. PCRs were performed in a 2720 ThermoCycler (Applied Biosystems, Life Technologies, 
United Kingdom). 
The selected primers were then combined in the same proportion for multiplex PCRs (three 
individual multiplex PCRs for each virus and one multiplex PCR for simultaneously detection of 
the three viruses). The multiplex PCRs were performed using the same conditions used in 
singleplex reactions. In the case of some HIV-1 samples with weak amplifications due to low 
viral loads, a second PCR with additional 20 cycles was performed using the PCR products (1 
μL) from the first PCR as template.  
We tested the sensitivity of the individual multiplex PCRs using gradients of primer annealing 
temperatures between 48 °C to 65 °C with one sample from each virus (1IV135 for HIV-1, 
CV1A-6 for HCV and BV151 for HBV). A second sensitivity test was performed with serial 
dilutions of viral concentrations. In this case, a sample of each virus of known viral load (sample 
1IV001 with 44,000 copies/mL, CV1A-6 with 107,152 IU/mL and BV151 with 81,600 IU/mL) was 
diluted by a factor of two. The specificity tests were performed using samples from the three 
viruses and human DNA from an uninfected individual.  
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We validated the final multiplex PCR using co-infections samples and artificial co-infections 
made by mixing cDNA/DNA from different samples. The artificial co-infection number 1 is a 
mixture of 1IV268, CV753 and BV839 genetic material, while the artificial co-infection number 2 
is a mixture of 1IV400, CV679 and BV646. PCRs were performed using the same conditions as 
previously described. 
 
Electrophoretic separation and sequencing  
The PCR amplified products were separated by electrophoresis on a 2 % agarose gel 
containing 1 μL of GelRed (Biotium, USA) at 140 V during 50 minutes. A PCR product volume 
between 3 to 5 μL was carried out in agarose gels. The fragments were visualized under UV 
light in a Molecular Imager® ChemiDocTM XRS Imaging System (Bio Rad, USA) with Quantity 
One software v4.6.9 (Bio Rad). 
The two samples from each virus used to test the PCR primers by singleplex PCR were 
sequenced in both directions with the same primers used for PCR in order to confirm the target 
sequence. PCR products (1.5 µL) were purified with ExoSAP-IT® (USB, Affimetrix, USA) 
according to the manufacturer’s recommendations. Sequencing of purified samples (2.5 µL) 
was performed as follows: 5 µL reactions mixtures were prepared by combining 2 µL of Big 
Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) with 0.5 µL of primer (2 µM). 
Thermal cycler conditions were: 96 °C for 2 min, 35 cycles at 96 °C for 15 s, 50 °C for 9 s and 
60 °C for 2 min and one final hold at 60 °C for 10 min. Sequencing reaction products were 
purified using Sephadex™ G-50 Fine DNA Grade columns (GE Healthcare, United Kingdom) 
according to the manufacturer’s recommendations. Purified samples were added to 12 µL of HI-
DI formamide (Applichem, Germany). Sequencing was performed in a Genetic Analyzer 3130xl 
sequencer (Applied Biosystems), according to the manufacturer’s recommendations. Sequence 
analysis was performed using Sequencing Analysis software v5.2 (Applied Biosystems) and 
Geneious version 5.4 created by Biomatters [52].  
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Results 
Selection of PCR primers and target regions 
Conserved regions were primarily identified using the identity option of the Geneious software 
version 5.4 [52]. A total of 16 conserved regions for HIV-1, 26 for HCV and 20 for HBV were 
selected. The conserved regions were chosen as potential primer-binding sites with 17 to 26 nt 
(Table S2) and were distributed throughout the viral genomes (Fig. S1). 
In the case of HIV-1, the average number of polymorphic positions in conserved regions was 
9.89 nt, with a minimum of 4 nt in HIV1_496R (with a total length of 18 nt) and a maximum of 16 
nt for HIV1_9581R (with a total length of 18 nt). In the case of HCV, the average number of 
polymorphic positions was 9.61 nt, with a minimum value of 3 nt in HCV_16F and HCV_250F 
(with a total length of 17 and 20 nt, respectively)  and a maximum value of 16 nt in HCV_3661R 
and HCV_8810R (with a total length of 23 and 20 nt, respectively). Despite the high number of 
sequences (n=387) in the HBV alignment, the average number of polymorphic positions in 
conserved regions was lower (average = 6.91 nt) than in the other viruses. The HBV presented 
a minimum of two polymorphic positions in HBV_1895R (with a total length of 19 nt) and a 
maximum of 10 nt in HBV_970F and HBV_2809F (with a total length of 23 and 22 nt, 
respectively), as described in table S2. 
We have avoided selecting primers with polymorphisms in the last five bases at the 3’ end in 
order to increase the primers specificity. Overall, 53 out of 66 primers were designed to have 
two or less polymorphic positions in the last five bases. It is interesting to notice that primers 
located in certain genomic regions were highly conserved, such as the HIV-1 LTR and the HCV 
5’ untranslated region, 5’UTR (Fig. 1A and B).  
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In fact, the LTR and 5’UTR are often used for the design of PCR primers, possibly by being 
more conserved [53, 54]. However, some sequences included in the alignments were 
incomplete for those peripheral regions, which may help to explain the apparent high 
conservation, i.e., less polymorphisms are expected with less represented sequences (Table 
S2). The lowest average number of polymorphic positions in HBV was found in X and C, 
although only two primers were designed in that region. 
The target regions were also selected to define genomic segments conserved in length across 
the sequence alignment, meaning that all viruses would yield amplicons with a similar length. 
This aspect is important if the length of the region is to be used for identification purposes. The 
standard deviation of the mean length of the target regions varies between 0 nt (i.e., no length 
variation) observed in regions from the three viruses to the maximum values of 0.4 nt in HIV-1 
(HIV_LTR, HIV1_169 and HIV1_434), 4 nt in HCV (HCV_320) and 15.1 nt in HBV (HBV_184). A 
high standard deviation (7.4 nt) was observed in the marker HBV_269. The variations in the 
range of 0.4 to 7.4 nt are smaller enough not to cause visible changes in the mobility of bands in 
agarose gel electrophoresis. However, the length variation of 15.1 nt in the HBV_184 marker 
may cause visible changes in the separation of bands, requiring caution if used for virus 
identification in multiplex PCR. Interestingly, this difference results from a 33 nt deletion 
common to all HBV genotype D viruses (Fig. 2). 
 
Fig. 1: Average number of polymorphic positions on PCR primers located in (A) HIV-1, (B) HCV and (C) 
HBV genomic regions. The polymorphisms were determined in the multiple sequence alignments made 
for each virus. The whiskers represent standard deviation of the mean. 
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The PCR primers were located throughout the entire genome of the three viruses, showing that 
conserved regions suitable for primer design can be found in different coding and non-coding 
regions (Fig. S1). Moreover, we were also able to design PCR primers in all genomic regions 
with the required parameters for efficient primer binding, such as a 17 to 26 nucleotide length 
and an expected melting temperature between 57.5 and 62.9 °C (Table S2). 
 
Target validation by singleplex PCR 
The selected targets regions (eight for HIV-1, 14 for HCV and 11 for HBV) were amplified by 
singleplex PCR to test the amplification efficiency. Two plasma samples of infected individual 
with each virus were used: 1IV001 and 1IV003 for HIV-1, CV001 and CV002 for HCV and 
BV013 and BV839 for HBV. The two HBV samples correspond to different genotypes (A for 
BV013 and D for BV839), while no genotype information was available for the other four 
samples. 
From the eight HIV-1 target regions, five were successfully amplified in both samples (Fig. 3A). 
The intensity of the amplified products was lower in sample 1IV003 than in sample 1IV001 
probably due to the low viral load of the former (15,400 copies/mL for 1IV003 and 44,000 
copies/mL for 1IV001). This difference was particularly marked in the fragment HIV1_108, 
although the amplification in 1IV003 is still detectable. A total of seven regions from the 14 
selected in HCV were amplified in both samples with similar intensity (Fig. 3B). The HCV targets 
HCV_88 and HCV_100 were of difficult distinction in agarose gel electrophoresis due to their 
similar sizes (88bp and 100bp). The 11 HBV target regions were successfully amplified in both 
samples (Fig. 3C). The 33 nt deletion common to all HBV genotype D (Fig. 2) is clearly visible in 
Fig. 2: Partial HBV sequence alignment. The region with a 33 nt gap is observed only in genotype D viral 
sequences. 
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the target region HBV_184, with two bands of predicted lengths of 184 bp (sample BV013, 
genotype A) and 151 bp (sample BV839, genotype D). It is interesting to notice that the PCR 
primer pair HBV_2809F and HBV_2992R can be used to discriminate HBV genotype D viruses 
from other genotypes. In any case, this target is not suitable for inclusion in the multiplex PCR to 
detect HBV due to the length variation that generates bands with different sizes that can 
confound the interpretation of results. 
 
 
Overall, the observed band lengths on agarose gels are in agreement with the expected sizes 
predicted in the multiple sequence alignments. The separation of amplified fragments by 
agarose gel allows for a good discrimination of target regions, with exception of HCV_88 and 
HCV_100 targets whose length difference is small (Fig. 3B).  
The sequencing of all products amplified by singleplex PCRs confirmed that all target regions 
were being correctly amplified (data not show).  
 
Target validation by multiplex PCR and reproducibility analysis 
The five HIV-1 target regions successfully amplified by singleplex reaction were all included in a 
multiplex PCR for specific detection of HIV-1 by combining all primers in equal proportions. 
From the seven HCV target regions, only the target HCV_100 was excluded because of the 
Fig. 3: Singleplex PCR amplifications of 5 HIV-1 (A), 7 HCV (B) and 11 HBV (C) target genomic regions. 
Only the target regions with positive amplifications are shown. Two samples for each virus were used to 
test all designed PCR primer pairs. NC - negative control; L -100 bp DNA ladder. 
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proximity in length to the fragment HCV_88. We selected five HBV fragments to be integrated in 
the final HBV multiplex PCR (Fig. 4). 
 
As expected, we observed bands resulting from cross-ampliﬁcations between primers designed 
for different targets. For instance, two bands of approximately 410 bp and 689 bp were 
observed in the HIV-1 multiplex PCR profile (Fig. 5), resulting from amplifications between 
primers HIV1_1292F and HIV1_1609R (410 bp) and HIV1_4377F and HIV1_5062R (689 bp). 
These extra bands did not interfere with the expected proﬁle. In total, the HIV-1 multiplex PCR 
had the expected five amplified products plus two bands resulting from primers of different pairs, 
the HCV had the six expected amplicons and one extra from cross-ampliﬁcations and HBV had 
five amplicons and two extra amplified products (Fig. 4). 
The reproducibility of the assay was assessed by testing multiple cases of individuals affected 
with each one of the virus. Firstly, 32 samples of HIV-1 infected individuals were typed using the 
HIV-1 multiplex PCR. At least one of the five target region was amplified in all HIV-1 samples 
(Fig. 5). Each of the target region was amplified in at least 50 % of the samples (Fig. 6A). 
 
 
Fig. 4: Expected band pattern resulting from the multiplex PCRs for HIV-1, HCV and HBV. The multiplex 
PCRs were designed to originate 5 HIV-1, 6 HCV and 5 HBV amplicons, However, the additional bands 
highlighted with ‘EX’ are those hat can result from the m lification with primers from different target
regions. 
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Fig. 5: Screening of samples with the HIV-1 multiplex PCR. The agarose gels show the amplified 
products (108, 133, 169, 222 and 300 bp) obtained in 32 HIV-1 samples.* - samples with a second PCR 
(20 cycles); NC - negative control; L - 100 bp DNA ladder. 
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The target region HIV1_108 was the one with more positive amplifications (84.38% of the 
samples), while HIV1_300 had the lowest amplification success (50% of the samples), as 
shown in Fig. 6A. The smallest amplicons (e.g., HIV1_108) were amplified more often than the 
largest regions (e.g., HIV1_300). 
When considering the amplification success per genotype, all HIV-1 makers except HIV_133 
were amplified in samples from all genotypes (Fig. 5B). The lack of HIV1_133 amplification in 
genotype A1 may be influenced by the reduced sample size of this genotype (n=2), suggesting 
that additional samples should be tested (Fig. 6B). 
About 31.3 % of the HIV-1 samples had amplifications in the five regions, while only 9 % of 
samples had a single amplification (Fig. 6C). On average, at least 2.5 target regions were 
amplified in HIV-1 genotypes (Fig. 6D). The majority of samples with the five amplified targets 
are from genotype B (Fig. 6E). The genotype G samples had more amplified target regions on 
average (4.5) than the others, when not considering those samples whose genotype is unknown 
(Fig. 6D). Nevertheless, the low sample size (n=2) of genotype G prevents further conclusions 
The data suggests that there might be a correlation between the viral load values and the 
number of amplified regions. The two samples with the highest viral loads had all regions 
amplified, while most samples with a single amplified region have less than 500 copies/mL (Fig. 
6F). However, some samples with low viral loads yield amplifications for all target regions, 
Fig. 6: Descriptive results of the screening of 32 samples with the HIV-1 multiplex PCR. (A) Percentage of 
samples with positive amplifications for the 5 HIV-1 target regions. (B) Frequencies of positive 
amplifications for the 5 HIV-1 target regions considering the different HIV-1 genotype (B, C, A1, G, 
complex and unknown). (C) Distribution of samples according to the number of amplified target regions. 
(D) Average number and standard deviation of amplified target regions per HIV-1 genotype. (E) Genotype 
distribution of samples amplified for all target regions. (F) Distribution of the number of amplified regions 
considering the viral load. 
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suggesting that other factors might explain the different amplification efficiencies across 
samples. 
The reproducibility of the multiplex PCR assay for HCV was assessed by testing 26 samples of 
infected individuals. In all cases, at least one HCV marker was amplified (Fig. 7). 
 
Each target region was amplified in at least 62 % of the samples. The marker HCV_206 was the 
one with the highest amplification efficacy (92.31% of the samples), while marker HCV_124 was 
amplified in 61.54 % of the samples (Fig. 8A).  
 
 
 
Fig. 7: Screening of samples with the HCV multiplex PCR. The agarose gels show the amplified products 
(88, 124, 169, 206, 265 and 320 bp) obtained in 26 HCV samples. NC - negative control; L - 100 bp DNA 
ladder. 
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In the case of HCV, the largest target regions had the highest amplification success (markers 
HCV_206 and HCV_320 with an amplification efficiency of 92.31 % and 88.46 %, respectively). 
When taking into account the genotypes, genotype 1A samples were amplified for the six 
markers (Fig. 8B). All samples whose genotype is unknown had the six target regions amplified. 
The genotype 3 samples had the highest amplification frequency in the largest markers, 
HCV_206, HCV_265 and HCV_320. The single sample of genotype 4 was only amplified for 
marker HCV_169 (Fig. 8B). 
Half of the HCV samples were amplified for all target regions, while only 4 % of the samples 
(n=1) had a single amplified region (Fig. 8C). The average number of amplified in genotypes 1A 
samples was 5.78 ± 0.44 regions and in in genotype 3 was 3.42 ± 1.51 (Fig. 8D). Overall, the 
samples with the highest number of amplified regions were found in all genotypes, with the 
Fig. 8: Descriptive results of the screening of 26 samples with the HCV multiplex PCR. (A) Percentage of 
samples with positive amplifications for the 6 HCV target regions. (B) Frequencies of positive 
amplifications for the 6 HCV target regions considering the different HCV genotype (3, 1A, 4 and 
unknown). (C) Distribution of samples according to the number of amplified target regions. (D) Average 
number and standard deviation of amplified target regions per HCV genotype. (E) Genotype distribution 
of samples amplified for all target regions. (F) Distribution of the number of amplified regions considering 
the viral load. 
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exception of genotype 1A (Fig. 8E). However, additional genotype 1A samples (only one was 
tested in this work) are necessary to confirm these results. 
Our results suggest that samples with the highest viral loads tend to have more amplified 
regions, although some samples with low viral loads also had six amplified regions (Fig. 8F).   
Although the low number of HBV samples (n=9) used to test the reproducibility of HBV multiplex 
PCR requires cautious interpretation, we found that all tested samples yielded positive 
amplifications (Fig. 9). 
 
The largest markers tend to have a better amplification success. For instance, the HBV_231 
(231 bp) target region had the highest amplification success (88.89 % of the samples), followed 
by HBV_188 (188 bp) and HBV_300 (300 bp), amplified in 77.78 % of the samples. The marker 
HBV_122 (122 bp) had the lowest amplification success, being only amplified in 33.3 % of the 
cases (Fig. 10A). 
 
 
 
Fig. 9: Screening of samples with the HBV multiplex PCR. The agarose gels show the amplified products 
(89, 122, 188, 231 and 30 bp) obtained in 9 HBV samples. NC - negative control; L - 100 bp DNA ladder. 
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The HBV genotype A samples were amplified for all target regions, while genotype D samples 
ware amplified for four target regions, missing the amplification of HBV_122 (Fig. 10B). Thus, 
33.3 % of the samples had the maximum number of amplifications (Fig. 10C), being from 
genotype A or unknown (Fig. 10E). The average number of amplified regions in genotype D was 
3.67 ± 0 (Fig. 10D). 
There is a clear tendency for samples with the highest viral loads (>22,600 IU/mL) to have a 
better amplification success (four or five amplified regions), while samples with the lowest viral 
loads (< 20 IU/mL) only amplify one or two regions (Fig. 10F). 
 
 
Fig. 10: Descriptive results of the screening of 9 samples with the HBV multiplex PCR. (A) Percentage of 
samples with positive amplifications for the 5 HBV target regions. (B) Frequencies of positive 
amplifications for the 5 HBV target regions considering the different HBV genotype (A, D and unknown). 
(C) Distribution of samples according to the number of amplified target regions. (D) Average number and 
standard deviations of amplified target regions per HBV genotype. (E) Genotype distribution of samples 
amplified for all target regions. (F) Distribution of the number of amplified regions considering the viral 
load. 
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Sensitivity and specificity of the multiplex PCR assays 
The sensitivity of the multiplex PCR assays was tested by two different approaches: gradients of 
primer annealing temperatures and gradients of viral concentration in samples. In the first 
approach, we carried out three multiplex PCRs, one for each virus, using annealing 
temperatures between 48 °C to 65 °C. All target regions of the HIV-1 multiplex PCR yielded 
positive amplifications at a range of temperatures from 48 °C to 58.3 °C. The amplification of the 
HIV1_108 and HIV1_222 targets started to disappear at temperatures above 58.3 °C (Fig. 11A).  
It is further noted that nonspecific amplifications were not observed at low temperatures (48 °C). 
The HCV multiplex PCR amplified well at temperatures between 54.5 °C and 58.3 °C. The 
amplification of some HCV target regions lost quality at temperatures below 54.5 °C. On the 
other hand, the smaller amplicons (HCV_88 and HCV_124) were not amplified at temperatures 
above 58.3 °C (Fig. 11B). Finally, the HBV multiplex PCR amplified better at temperatures 
below 54.5 °C, although all markers were amplified in the range of tested temperatures (Fig. 
11C). 
 
 
The second approach to test the sensitivity of the multiplex PCRs was based on a serial dilution 
of viral concentrations. The amplification of the diluted samples with the multiplex PCR revealed 
that the detection limit for HIV-1 was between 687.5 copies/mL (1:64) and 343.75 copies/mL 
(1:128). The markers HIV1_133, HIV1_300 and HIV1_222 were lost at concentrations equal or 
lower than 2,750 copies/mL, dilution 1:16 (Fig. 12A). In the case of HCV, loss of amplifications 
was observed at concentrations between 837.13 IU/mL (1:128) and 418.56 IU/mL (dilution 
1:256), with good amplifications observed until the sample concentration of 1674.25 IU/mL, 
dilution 1:64 (Fig. 12B). The HBV serial dilution showed that amplifications failed at 
Fig. 8: Sensitivity test of multiplex PCR using gradients of annealing temperatures between 48 °C and 65 
°C for HIV-1 (A), HCV (B) and HBV (C). One sample of each virus (1IV135, CV1A-6 and BV151) was 
used. NC - negative control (at the lowest temperature); L - 100 bp DNA ladder. 
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concentrations between 39.84 IU/mL (1:2048) and 19.92 IU/mL (1:4096). However, no 
amplification was observed in markers HBV_89 and HBV_122 at concentrations below 19.92 
IU/mL, dilution 1:4096 (Fig. 12C). 
Finally, we tested the specificity of the three multiplex PCRs by using samples of virus not 
targeted by each one of the assays. For example, we tested the HIV-1 multiplex against HCV 
and HBV samples. We also tested the assays using human DNA from an uninfected individual. 
Our results demonstrate that the three multiplex PCRs are specific regarding the tested viral 
samples, since no nonspecific amplifications were observed, including in human DNA (Fig. 13A 
and 13B). 
Fig. 9: Sensitivity test of multiplex PCRs using gradients of viral concentration for HIV-1 (A), HCV (B) and 
HBV (C). The starting point of concentration for HIV-1 sample 1IV001 was 44,000 copies/mL, for  HCV 
sample CV1A-6 was 107,152 IU/mL and for HBV sample BV151 was 81,600 IU/mL. NC - negative 
control); L - 100 bp DNA ladder. 
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Multiplex PCR for simultaneous detection of HIV-1, HCV and HBV 
We selected six target regions (two for each virus) among the 16 target regions initially tested 
for all viruses (Fig. 4). The regions were chosen by having different lengths so the different 
viruses can be distinguished. The selected markers were HIV1_108 and HIV1_169 for HIV-1, 
HCV_206 and HCV_320 for HCV and HBV_89 and HBV_231 for HBV (Fig. 14). We also 
selected the regions with better amplification efficiencies in the individual multiplex PCRs of 
each virus (Fig. 6A, 8A and 10A). 
 
 
The multiplex PCR was tested by typing four viral co-infections (three HIV-1/HCV co-infections 
and one HVI-1/HBV co-infection) and two artificial co-infections (Fig. 15). The two viruses in 
each sample were correctly identified in 83.3% (5 out of 6) of the co-infections. One sample with 
a HIV-1/HCV co-infection (CV1IV91) had the four expected amplicons: the two HIV-1 amplicons 
Fig. 11: Expected band pattern of the multiplex PCR for simultaneous detection of HIV-1, HCV and HBV. 
The multiplex PCR includes two specific target regions from each virus (expected amplicons for HIV-1 
indicated in red, for HCV in blue and for HBV in green). The image on the right shows a 100 bp ladder. 
Fig. 10 (previous page): Specificity tests for the HIV-1, HCV and HBV multiplex PCRs. The agarose gels 
show the result of the test of the multiplex PCR for HIV-1, HCV and HBV using (A) samples of the three 
viruses and (B) human DNA. The 18S gene was used as positive control for presence of human DNA. NC 
- negative control); L - 100 bp DNA ladder. 
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(108 bp and 169 bp) and the two HCV amplicons (206 bp and 320 bp). The CV1IV97 sample 
with HIV-1/HCV co-infection only amplified two target regions (one for each virus, HIV1_108 and 
HCV_206), allowing the detection of both viruses. Unfortunately, the sample CV1IV13 only 
amplified the two HCV markers with an expected length of 206 bp and 320 bp. The absence of 
amplification of the HIV-1 regions was probably due to the low HIV-1 viral load (41 copies/mL), 
which was much lower than the estimated for HCV (3,180,000 IU/mL). The BV1IV45 sample 
had the four target regions amplified, namely the two HIV-1 amplicons (108 bp and 169 bp) and 
two HBV amplicons (89 bp and 231 bp), as shown in Fig.15A.  
The two artificial co-infections typed with the multiplex PCR showed amplifications for all target 
regions (Fig. 15B), suggesting that it can work in the presence of genetic material from the three 
target viruses. 
 
 
 
 
 
  
Fig. 12: Multiplex PCR for simultaneous detection of HIV-1, HCV and HBV (A) Agarose gels showing the 
amplifications with the multiplex PCR of (A) 3 HIV-1/HCV and 1 HIV-1/HBV co-infections and (B) 2 
artificial co-infections with the three viruses. NC - negative control; L - 100 bp DNA ladder. 
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Discussion 
The use of accurate methods for clinical diagnosis is an important aspect to control viral 
infections. Unfortunately, some of the available methods lack detection accuracy and are 
expensive and time-consuming. It is therefore of paramount importance to develop methods for 
the simultaneous identification of different viruses at low cost and with high efficiency levels. In 
this work, a multiplex PCR assay for simultaneous identification of three blood-borne viruses 
(HIV-1, HCV and HBV) and three individual multiplex PCRs for identification of each virus were 
developed.  
One advantage of our methods is the placement of PCR primers on the most conserved viral 
genomic regions, allowing the detection of different virus genotypes. At least one region was 
amplified in all tested samples (n=70), while 26 samples had amplifications in all targeted 
regions (31.3 % of HIV-1, 50 % of HCV and 33.3 % of HBV samples). It should be noted that 
the HCV multiplex had the best amplification performance despite having six target regions on 
the multiplex PCR. The low percentage of HIV-1 samples that amplify for all markers might 
result from the high mutation rate and extreme genetic diversity among HIV-1 subtypes, which 
differ from each other by ~30 % over the complete genome [55]. The low percentage may also 
result from the low viral loads of HIV-1 samples when compared with those from HCV (Table 
S1). The HBV has low genetic diversity values, with only 8 to 15 % of divergence between the 
major genotypes [56]. However, the success of amplification of all HBV markers (33.3 %) was 
similar to the observed in HIV-1 (3.31 %). This result can be influenced by the low HBV samples 
size and by the lack of amplification observed in marker HBV_122, which only amplified in three 
HBV samples. The multiplex PCR for detection of the three viruses identified correctly all 
viruses present in 83.3% of the tested co-infections. 
Because the genome of the three viruses is relatively short, PCR amplifications between 
primers designed for different markers are inevitable if several markers are included in a 
multiplex PCR. In order to avoid this problem, we have selected markers with interactions that 
result in large amplicons that do not overcome the desired target regions. Only one of the 
predicted extra amplification (EX_HIV1_410) was observed in the HIV-1 multiplex PCR (Fig. 5) 
and two predicted extra amplifications (EX_HBV_428 and EX_HBV_517) were observed in the 
HBV multiplex PCR (Fig. 9). In fact, such extra amplifications can add additional information to 
the multiplex PCR assay. Nevertheless, such extra amplifications can compete with the desired 
target regions in the PCR and deplete some of the PCR reagents. However, we did not notice a 
significant decrease of the PCR amplifications due to this factor. In any case, we have avoided 
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these interactions in the multiplex PCR for the simultaneous identification of the three viruses, 
since only two markers from each one are being used. No extra amplifications were observed in 
this multiple PCR (Fig. 15). 
We have also optimized our assays taking into account some PCR conditions, like the melting 
temperature and the number of cycles. The gradients of annealing temperatures showed that 
robust amplifications can be obtained between 54.5 °C to 58 °C for HIV-1, HCV and HBV. 
However, the multiplex PCR performed very well at lower or higher temperatures. For instance, 
the HBV multiplex PCR amplified all target regions without non-specific amplifications at 51.2 °C 
and 48 °C. These results suggest that most markers included in our multiplex PCRs can be 
used in very different conditions, such as in real-time PCR or combined with other markers in 
different multiplex PCRs. 
The use of short target regions is usually an advantage in the analysis of low quantity/quality 
template. For instance, HIV1_108, HIV_133 and HIV1_169 were the markers with the highest 
amplification success. Nevertheless, better amplifications were observed for the largest HCV 
and HBV target regions (Figs. 8A/B and 10A/B). 
Our screening of samples from infected individuals allowed us to evaluate the amplification 
success of the selected target regions. Despite our efforts to design the best possible PCR 
primers in such highly variable genomes, some target regions were not amplified in some 
samples (Fig. 6A/B, 8A/B, 10A/B). The absence of amplification could be related with the level 
of conservation in the primer binding sites. It is well known that polymorphisms in primer-binding 
sites can lead to false-negative results, which are likely in HIV-1 and HCV where an extreme 
genetic diversity prevail [57]. 
In order to test such hypothesis, the conservation values for each primer (Table S2) and the 
success of PCR amplifications were compared for each target region (Fig. 6A, 8A, 10A). 
However, we found that HIV-1 and HBV markers with the highest amplification efficiency 
(HIV1_108 and HBV_231) are those with more polymorphic positions, on average (Table S2). 
The HCV_206 and HCV_320 markers had the highest success of amplification (92.31 % and 
88.46 % of samples, respectively) as well as less polymorphic positions on average than the 
other markers. The exception is HCV_169 which had the lowest number of polymorphic 
positions and was amplified in 69.23 % of samples. In any case, the localization of HCV_169 in 
the genomic region less represented in the sequence alignment (5’UTR) may explain the low 
number of polymorphisms.  
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The different efficiencies in PCR amplifications observed among marker may result from other 
factors inherent to the PCR. The failure to amplify some HIV-1 target regions in samples with 
low viral load (which required a second PCR) suggests that the template concentration may 
explain the absence of amplification in some samples (Fig. 6F, 8F, 10F). In any case, all HIV-1 
samples amplified at least one target region in the first PCR. Other factors may also influence 
our results, such as template nucleotide composition, formation of secondary structures in the 
template or primers, primer interactions, etc. Further validation studies are necessary to identify 
the causes of the missing amplifications. 
One of the most notorious advantages of our method is the use of several target regions, which 
presents a clear advantage over methods targeting a single region. In cases where one or more 
target regions fail to amplify by the reasons described above or others, a correct identiﬁcation is 
still possible based on the information from the remaining regions. For example, the presence of 
HIV-1 was detected in 1IVB8 sample with only a single amplified region of the multiplex PCR. 
Therefore, the occurrence of variability in primer-binding sites and other causes of missing PCR 
amplifications do not pose serious problems to our approach by the use of multiple target 
regions (Fig. 4). Our screening of clinical samples revealed that at least one of the markers was 
amplified in all cases (Fig. 5, 7, 9). 
Other available methods either target a single genomic region (prone to false-negative results) 
or require multiple reactions, making the method expensive and time-consuming [29]. For 
example, real-time PCR assays using nonspecific DNA binding probes (e.g., SYBR Green I) are 
limited to the detection of the total amount of amplification products, which is prone to false-
positives by non-specific amplifications or false-negatives by targeting usually a single genomic 
region [31]. The real-time PCR assays using viral specific probes (e.g. TaqMan probes) are 
expensive and limited in the number of probes that can be used simultaneously [31]. The 
AMPLINAT MPX test is an example of such type of assays [57]. This TaqMan real-time PCR is 
unable to discriminate among the three viruses selected in this work, requiring a secondary 
diagnostic step using virus-specific amplifications. The COBAS TaqMan HIV-1 or HCV (Roche 
Molecular Systems, Inc.) is based on singleplex PCR and, thus, prone to false-negative results. 
The lack of sensitivity in NAT assays is aggravated when using a pool of mixed samples to 
reduce costs and labour in some screening plans [30]. Our multiplex PCR for simultaneous 
identification of the three viruses may reduce the need of using pools of samples since the 
detection of these viruses is possible in a single reaction. 
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A landmark in clinical diagnosis was the implementation of serological tests and NAT assays for 
detection of HIV-1, HCV and HBV, which reduced significantly the risk of viral transmission by 
blood donations. Nevertheless, a residual transmission risk remains to be eliminated [58]. The 
absence of antiviral antibodies to be detected by serological tests remains the main cause of 
the residual risk of viral transmission in blood transfusions [20]. Early in HIV-1 infections, prior to 
p24 antigen positivity, HIV-1 viral load range from 2x102 to 1x106 copies/mL. Studies report that 
a titer of HCV RNA can be very high in early infection, i.e., HCV viral load can reach 1x105 – 
1x106 IU/mL and this value is maintained until antibody detection [58]. During HBV 
seroconversion window period, HBsAg is the earliest detectable serologic marker [14]. 
However, HBsAg is often undetectable and serological tests result in false negatives. For 
example, AMPLINAT MPX system detects HBV DNA in samples that were negative for HBsAg 
test. In the window period, HBV viral load is ranging between 10 – 1x104 IU/mL [57, 59]. By 
these reason, knowing the detection limit of a method is of great relevance.  
In order to assess the sensitivity of our assays, one plasma sample of each virus was serial 
diluted to determine detection limits. The limits determined for the multiplex PCR were 343.75 - 
687.5 copies/mL for HIV-1, 418 - 837.13 IU/mL for HCV and 19 - 39.84 IU/mL for HBV. These 
values suggest that our multiplex PCRs should be sufficient to detect viral infections during the 
window period. In any case, HIV-1 samples with viral loads lower than 343.75 copies/mL and 
HBV samples with viral loads lower than 19 IU/mL may not be correctly diagnosed by this 
method with the conditions implemented in the PCR (e.g., 40 cycles for HIV-1 and 35 cycles for 
HBV). In these cases, a second PCR with more cycles using as template the PCR products 
from a first PCR could be used to guarantee the absence of viral genetic material. We used a 
second PCR for a better amplification of some markers in 11 HIV-1 samples with low viral loads, 
although the first PCR was always enough for HIV-1 detection. Other techniques face the same 
problem when screening HIV-1 samples with viral loads. For instance, 46.8 PCR cycles were 
necessary in the real time PCR array described by Pripuzova et al [26] to detect HIV-1 in a 
sample whit a viral load of 51 copies/mL.  
It should be noted that the viral concentrations on the plasma samples used to calculate the 
detection limits were estimated using a real-time PCR performed on the laboratories providing 
the samples. Although it is a good approximation to real values, it is possible that our RNA 
isolation and cDNA synthesis (HIV-1 and HCV) or DNA extraction (HBV) would lead to different 
viral concentrations in the template samples used in the serial dilution PCR. Future sensibility 
tests using standard reference samples will be used to confirm the multiplex PCR detection 
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limits. The detection limits of the multiplex PCR for the simultaneous identification of the three 
viruses should not differ significantly from the estimated for the individual multiplex PCR, since 
the same target regions are being used. However, a sensitivity test for this multiplex PCR is 
recommended, considering that interactions in the new mixture of primers and other PCR 
factors may affect the amplification efficiency. 
We also tested the specificity of our multiplex PCR assays using genetic material from human 
and non-target viruses. The assays proved to be 100 % specific for the targeted virus, since no 
unspecific amplifications were detected. By this reason, false positive results are unlike using 
our methods.  
In conclusion, we confirmed previous studies that demonstrate the advantages of using 
multiplex PCR for viral identifications in various clinical and epidemiological settings [38]. In this 
thesis, a conventional multiplex PCR was developed for simultaneously detection of the major 
blood-borne viruses, HIV1-, HCV and HBV. The simplicity of the assays and the fact that the 
detection is based on the amplification of several viral genomic regions are the two main 
advantages. The identification can be obtained using conventional agarose or acrylamide gels, 
with no need for expensive sequencing or real-time PCR apparatus. These multiplex PCR 
assays are sensitive and specific, although more tests are required (e.g., standards samples) to 
obtain greater precision in sensitivity and specificity. The direct detection of multiple viruses in a 
single reaction is an improvement for the screening of samples in the clinical context or in blood 
banks. Our methods can also be used in early infant diagnosis, where serological tests have a 
high rate of false positives due to the detection of maternal antiviral antibodies in the infants 
[53]. Our multiplex PCRs can serve as a complement to techniques routinely used in 
laboratories or as a screening technique prior to other analyses, by reducing costs and 
increasing the accuracy of the detection. 
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Supplementary material 
Supplementary figures 
 
 
  
 
Fig. S1: Schematic representation of the localization of target regions (orange arrows) and PCR primers (green arrows) in HIV-1, HCV and HBV 
references genome sequences. 
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Supplementary tables 
Table S1: Description of the plasma samples used in this study. 
Virus Lab code Genotype Viral load  Virus Lab code Genotype Viral load 
H
IV
-1
 
1IV001 G 44000  
H
C
V
 
CV641 3A 4700000 
1IV002 A1 98500  CV683 4A/4C/4D 2670 
1IV003 nd 15400  CV679 3A 423000 
1IV400 G 43500  CV753 nd 1510000 
1IV127 A1 10900  CV3-1 3 67608.30 
1IV139 B 98200  CV3-2 3 19054.60 
1IV268 B 56900  CV3-3 3 4466.84 
1IV135 nd 412000  CV3-4 3 562341 
1IVB1 B 360  CV3-5 3 2344229 
1IVB2 B 2803  CV3-6 3 758578 
1IVB3 B 544436  CV3-7 3 10232929.92 
1IVB4 B 168891  CV3-8 3 34673.69 
1IVB5 B 20123  CV3-9 3 501187 
1IVB6 B 4130  CV3-10 3 1348962.90 
1IVB7 B 750  CV1 1A 52480.70 
1IVB8 B 118710  CV2 1A 181970 
1IVB10 B 953  CV3 1A 5623413.25 
1IVC1 C 16754  CV4 1A 13803.8 
1IVC2 C 4702  CV5 1A 1318257 
1IVC3 C 2214  CV1A-6 1A 107152 
1IVC4 C 824  CV1A-7 1A 3981072 
1IVC5 C 50998  CV1A-8 1A 1584893 
1IVC6 C 111  CV1A-9 1A 7943282 
1IVC7 C 759  
H
B
V
 
BV269 nd 237 
1IVC8 C 702  BV423 nd 20 
1IVC9 C Unknown  BV609 D 22600 
1IVC10 C 18728  BV646 D 3050 
1IVCP1 Complex 1044  BV839 D 89500 
1IVCP2 Complex Unknown  BV013 A 170000000 
1IVCP3 Complex 25510  BV151 nd 81600 
1IVCP4 Complex 56872  BV117 nd 20 
1IVCP5 Complex 585 
 
C
o
-i
n
fe
c
ti
o
n
s
 
CV1IV97 
1A (HCV), nd 
(HIV-1) 
1440000 /  
2650 
H
C
V
 
CV001 nd 2450000 
 
CV1IV13 
nd (HCV), nd 
(HIV-1) 
3180000 /  
41 
CV002 nd 9790000 
 
CV1IV91 
3A (HCV), nd 
(HIV-1) 
1880000 / 
110000 
CV003 3A 11000000 
 
BV1IV45 
A (HBV), nd 
(HIV-1) 
170000000 / 
43700  
The table describes the laboratory code, genotype and viral load of samples from HIV-1 (n=32), HCV (n=26) and HBV (n=8) infected individuals, as well as 4 samples from co-infected 
individuals (1 with a HIV-1/HBV co-infection and 3 with HIV-1/HCV co-infections). The units of the HIV-1 viral load is in copies/mL and of the HCV and HBV in IU/mL. 
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Table S2: Description of the target regions and PCR primers used in the multiplex PCRs for identification of HIV-1, HCV and HBV 
Target region  Primer 
V
ir
u
s
 
N
a
m
e
 
N
º 
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e
q
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e
n
c
e
s
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 a
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n
m
e
n
t 
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v
) 
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–
 3
’)
 
F
o
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/ 
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e
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e
 
T
m
 (
◦C
) 
L
e
n
g
th
 (
n
t)
 
N
º 
o
f 
v
a
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a
b
le
 
p
o
s
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io
n
s
 (
n
t)
 
N
º 
o
f 
v
a
ri
a
b
le
 
p
o
s
it
io
n
s
  
a
t 
3
’ 
e
n
d
 (
n
t)
 
H
IV
-1
 
HIV1_LTR 31 LTR 82.7 ± 0.4 
HIV1_414F CTCAGATCCTGCATATAAGCAG FW 60.1 22 7 0 
HIV1_496R CAGAGAGCTCCCAGGCTC RV 60.8 18 4 0 
HIV1_222
*
 170 gag 222 ± 0.0 
HIV1_1282F AGCCCAGAAGTGATACCCATG FW 61.2 21 8 1 
HIV1_1507R TCCTGCTATGTCACTTCCCC RV 60.5 20 10 3 
HIV1_108
*
 170 gag 108 ± 0.0 
HIV1_1583F GGATAATCCTGGGATTAAATAAAATA FW 58.4 26 11 1 
HIV1_1690R AGAACCGGTCTACATAGTCTCT RV 60.1 22 10 2 
HIV1_264 170 pol 264 ± 0.2 
HIV1_2466F ATAGGTAC GTATTAGTAGGACCT FW 60.3 24 15 2 
HIV1_2729R GAAAATCCATACAATACTCCAGTA RV 58.3 24 11 1 
HIV1_133
*
 170 pol 133.0 ± 0.1 
HIV1_3100F TGGATGATTTGTATGTAGGATCTGA FW 60.9 25 10 1 
HIV1_3232R AGGAATGGAGGTTCTTTCTGATG RV 60.9 23 9 1 
HIV1_300
*
 170 pol 300.0 ± 0.0 
HIV1_4377F ATGCATGGACAAGTAGACTGTAG FW 60.9 23 11 2 
HIV1_4676R TCCTTGACTTTGGGGATTGTAG RV 60.1 22 8 2 
HIV1_169
*
 170 pol 169.0 ± 0.4 
HIV1_4894F ATTTTCGGGTTTATTACAGGGACA FW 60.3 24 7 1 
HIV1_5062R TCACCTGCCATCTGTTTTCCA RV 59.5 21 9 2 
HIV1_434 170 tat. env 434.1 ± 0.4 
HIV1_7931F AGTCTGGGGCATCAAGCAG FW 59.5 19 11 2 
HIV1_8364R GTGAATATCCCTGCCTAACTC RV 59.5 21 13 5 
H
C
V
 
HCV_169
*
 140 5’UTR 168.8 ± 0.4 
HCV_16F GGGGCGACACTCCACCA FW 59.8 17 3 1 
HCV_205R CGTCCTGGCAATTCCGGTG RV 61.6 19 8 0 
HCV_249 140 5’UTR 248.9 ± 0.4 
HCV_16F GGGGCGACACTCCACCA FW 59.8 17 3 1 
HCV_264R ACACTACTCGGCTAGCAGTCT RV 61.2 21 4 2 
HCV_100 467 5’UTR 100 ± 0.0 
HCV_250F CTAGCCGAGTAGTGTTGGGT FW 60.5 20 3 1 
HCV_349R GTGCTCATGGTGCACGGT RV 58.4 18 5 3 
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Target region  Primer 
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HCV_304 471 Core  304 ± 0.0 
HCV_448F TGTTGCCGCGCAGGGGC FW 61.8 17 8 2 
HCV_751R ATGTACCCCATGAGGTCGG RV 59.5 19 8 2 
HCV_320
*
 471 E1  319.7 ± 4.0 
HCV_1299F TGGGATATGATGATGAACTGG FW 57.5 21 8 2 
HCV_1618R GCCGTGCTATTGATGTGCCA RV 60.5 20 10 1 
HCV_88
*
 471 NS3  88.0 ± 0.0 
HCV_3574F GCTGGACTGTCTACCACGG FW 61.6 19 12 2 
HCV_3661R TCTTGGTCCACATTGGTATACAT RV 59.2 23 16 2 
HCV_206
*
 471 NS3  206.0 ± 0.1 
HCV_4035F ACCGGCAGCGGTAAGAGC FW 60.8 18 9 3 
HCV_4240R AGGAACTTGCCGTAGGTGGA RV 60.5 20 11 2 
HCV_265
*
 471 NS3 265.0 ± 0.0 
HCV_4906F ACGCGGGCTGTGCTTGGT FW 60.8 18 10 1 
HCV_5170R CACTTCCACATCTGGTCCCA RV 60.5 20 11 0 
HCV_275 471 NS3 275.0 ± 0.0 
HCV_4906F ACGCGGGCTGTGCTTGGT FW 60.8 18 10 1 
HCV_5180R GCGGATCAAACACTTCCACAT RV 59.5 21 15 4 
HCV_167 471 NS4B  167.0 ± 0.0 
HCV_5622F TGGGCGAAGCACATGTGGAA FW 60.5 20 11 1 
HCV_5788R ACCCACCCCCCCAATATGTT RV 59.5 21 15 4 
HCV_77 471 NS4B  77.0 ± 0.0 
HCV_6081F CAATGGATGAACCGGCTAATAGC FW 62.9 23 8 1 
HCV_6157R TCGCTCTCCGGCACGTAGT RV 61.6 19 11 2 
HCV_97 471 NS5B  97.0  ± 0.0 
HCV_8614F CCTTCACGGAGGCTATGAC FW 59.5 19 12 1 
HCV_8710R ACGTTGGAGGAGCATGATGTTAT RV 60.9 23 13 4 
HCV_197 471 NS5B  197.0 ± 0.0 
HCV_8614F CCTTCACGGAGGCTATGAC FW 59.5 19 12 1 
HCV_8810R AGTGTGTCTTGCTGTCTCCC RV 60.5 20 16 2 
HCV_124
*
 471 NS5B  124.0 ± 0.1 
HCV_9167F CAAGTACCTCTTCAACTGGGC FW 61.2 21 8 0 
HCV_9290R GCTGTGATAAATGTCTCCCCC RV 61.2 21 13 3 
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HBV_101 385 P, S  101.0 ± 0.0 
HBV_56F CCTGCTGGTGGCTCCAGT FW 60.8 18 8 5 
HBV_156R ATGTTCGGTGCAGGGTCC RV 58.4 18 8 1 
HBV_139 386  P, S 138.9 ± 0.0 
HBV_16F CCTGCTGGTGGCTCCAGT FW 60.8 18 8 5 
HBV_194R CGAGCAGGGGTCCTAGGA RV 60.8 18 5 2 
HBV_231
*
 386 P, S 231.0 ± 0.1 
HBV_246F GTCTAGACTCGTGGTGGAC FW 59.5 19 7 2 
HBV_476R GACAAACGGGCAACATACC RV 57.5 19 7 1 
HBV_196 387 P, S 196.0 ± 0.5 
HBV_459F GTATGTTGCCCGTTTGTCCT FW 58.4 20 7 1 
HBV_645R GAGGCCCACTCCCATAGG RV 60.8 18 3 0 
HBV_300
*
 387 P, S 300 ± 0.5 
HBV_459F GTATGTTGCCCGTTTGTCCT FW 58.4 20 7 1 
HBV_758R CCCAATACCACATCATCCATAT RV 58.4 22 8 2 
HBV_269 387 P 268.6 ± 7.4 
HBV_970F CCTATTGATTGGAAAGTATGTCA FW 57.6 23 10 3 
HBV_1238R CGCATGCGCTGATGGCC RV 59.8 17 8 2 
HBV_142 386 P, X 142.0 ± 0.0 
HBV_1265F TCCATACTGCGGAACTCCT FW 57.5 19 7 3 
HBV_1406R AGGATCCAGTTGGCAGCACA RV 60.5 20 7 3 
HBV_89
*
 384 P, X 89.0 ± 0.0 
HBV_1516F ACCACGGGGCGCACCTC FW 61.8 17 8 1 
HBV_1604R ACGTGCAGAGGTGAAGCGA RV 59.5 19 8 2 
HBV_122
*
 385 X, C 122.0 ± 0.0 
HBV_1774F TAGGAGGCTGTAGGCATAAATTG FW 60.9 23 4 1 
HBV_1895R AAAGCCACCCAAGGCACAG RV 59.5 19 2 0 
HBV_188
*
 386 P, C 188.6 ± 1.8 
HBV_2301F CACCAAATGCCCCTATCTTATC FW 60.1 22 7 2 
HBV_2494R CCCGTAAAGTTTCCCACCTT RV 58.4 20 5 0 
HBV_184 387 P, S 174.3±15.1 
HBV_2809F CCTCATTTTGTGGGTCACCATA FW 60.1 22 10 1 
HBV_2992R GGTTGAAGTCCCAATCTGGA RV 58.4 20 8 2 
A total of 33 target regions are described by name, number of sequences in alignment, corresponding genomic region and mean length with standard deviation in nucleotides (nt). A 
total of 66 primers (forward and reverse) are listed by name, primer sequence in 5’-3’ orientation, melting temperature (°C), primer length (nt), number of polymorphic positions across 
alignments for the entire primer-binding region or for the last five bases at 3’ end. 
* 
denotes the target regions included in individual multiplex PCRs. 
